<DOC>
	<DOC>NCT02507388</DOC>
	<brief_summary>The purpose of this study is to assess the systemic pharmacokinetics (PK) of RTH258 in subjects (Japanese and non-Japanese ethnicity) with neovascular Age-Related Macular Degeneration (AMD).</brief_summary>
	<brief_title>Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration</brief_title>
	<detailed_description>This study has 2 arms with a 1:1 randomization. Randomization will be stratified by Japanese ethnicity. Half of the subjects in each arm will be of Japanese ethnicity. The other half of the subjects in each arm will be non-Japanese. Subjects in both arms will have visits through Day 84.</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Provide written informed consent; Active choroidal neovascularization (CNV) lesions secondary to AMD that affect the central subfield in the study eye; Best Corrected Visual Acuity (BCVA) ≥ 23 letters in the study eye at Baseline; Other protocolspecified inclusion criteria may apply. Any active ocular infection or inflammation; Treatment with aflibercept (EYLEA®), bevacizumab (AVASTIN®), ranibizumab (LUCENTIS®), pegaptanib (MACUGEN®), or an investigational drug for neovascular AMD prior to enrollment in the study, as specified in protocol; Ocular surgery in the study eye, as specified in protocol; Uncontrolled glaucoma in the study eye, as specified in protocol; Use of steroids in the study eye, as specified in protocol; Medical conditions that may prevent study completion; Pregnant or nursing (lactating) women; Women of childbearing potential unless using contraception; Uncontrolled blood pressure, as specified in protocol; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>